Fig. 1 · Structure

Documents & Downloads

Gastrodin (Gastrodine)

Cat. No. A10418 CAS 62499-27-8
Gastrodin (Gastrodine) is a polyphenol. It is the glucoside of 4-hydroxybenzyl alcohol (gastrodigenin).

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

In activated BV-2 microglia, gastrodin attenuated phosphorylation of IκB-α, CREB, ERK1/2, JNK and p38 MAPK. Responses were not consistently concentration dependent. These cellular readouts support signaling modulation without establishing direct inhibition of a molecular target. [1]

In peroxide-challenged HUVECs, gastrodin increased nuclear Nrf2 and HO-1, while the HO-1 inhibitor SnPPIX attenuated reductions in senescence markers. This supports pathway involvement, with limits from the pharmacological control design. [2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Gastrodin (Gastrodine) Research Summary

This section summarizes 4 in vitro studies and 1 in vivo study of Gastrodin (Gastrodine) from 3 published references. In vitro models include immortalized mouse BV-2 microglial cells; rat C6 astroglial cell line.

Gastrodin (Gastrodine) In Vitro Studies

Gastrodin reduced iNOS and COX-2 expression in LPS-stimulated BV-2 cells. The iNOS mRNA response at 30 µM lacked a significance marker; 40 and 60 µM were marked significant. These are expression endpoints rather than enzyme-activity measurements. [1]

In zinc-challenged C6 astroglial cells, 24 h gastrodin co-treatment improved the MTT viability signal at 50 and 100 µM. The 250 µM group lacked a significance marker, so a monotonic concentration-response relationship is not supported. [3]

Gastrodin reduced p16, p21 and SA β-gal senescence markers in peroxide-challenged HUVECs. The experiment concerns an induced cellular senescence model and does not establish prevention of vascular aging in animals or humans. [2]

Inflammatory enzyme expression in activated BV-2 microglia

Cell-based study · Immortalized mouse BV-2 microglial cells [1]

Gastrodin reduced inflammatory enzyme expression relative to LPS alone; iNOS mRNA at 30 µM lacked a significance marker. Protein evidence was representative immunofluorescence, not enzyme activity.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
iNOS mRNA normalized to β-actin and representative protein stainingRT-PCR / immunofluorescence mRNA: 40 and 60 µM marked p<0.05 versus LPS alone; 30 µM not marked significant. Mean ± SEM, three independent experiments.[1]
COX-2 mRNA normalized to β-actin and representative protein stainingRT-PCR / immunofluorescence mRNA reduced at 30, 40 and 60 µM, p<0.05 versus LPS alone. Mean ± SEM, three independent experiments.[1]

Literature-Reported Treatment Conditions

Treatment concentration
30, 40 and 60 µM
Exposure duration
1 h pretreatment, then 4 h stimulation
Method
Pretreatment before LPS (1 µg/mL); untreated and LPS-only controls.
Co-treatment
LPS is the inflammatory challenge, not a therapeutic combination.
Reported limits
Gastrodin vehicle, purity and lot analytical identity are not specified in the examined Methods. No gastrodin-only treatment group in the five-group design.
Methods and source locations

Compound reported in the paper: Gastrodin; Compound label in the paper: gastrodin

Findings apply to the named research material and specified model; no analytical or performance validation of an Adooq lot.

Figures 1–3; Methods: Cells and treatments, Double-immunofluorescence labeling assay, RT-PCR analysis, Statistical analysis

iNOS mRNA normalized to β-actin and representative protein staining: RT-PCR densitometry; representative double-immunofluorescence images. — Figure 2A–B and caption

COX-2 mRNA normalized to β-actin and representative protein staining: RT-PCR densitometry; representative double-immunofluorescence images. — Figure 3A–B and caption

Early phosphorylation responses in BV-2 microglia

Cell-based study · Immortalized mouse BV-2 microglial cells [1]

Gastrodin attenuated stimulus-induced phosphorylation of IκB-α, CREB and MAPKs. These are cellular associations rather than direct binding or purified-enzyme inhibition.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Phosphorylated IκB-α, CREB, ERK1/2, JNK and p38 MAPKNormalized immunoblot densitometry All three concentrations marked p<0.05 versus LPS alone. Mean ± SEM; three independent experiments. Total MAPKs were reported unchanged.[1]

Literature-Reported Treatment Conditions

Treatment concentration
30, 40 and 60 µM
Exposure duration
1 h pretreatment, then 30 min stimulation
Method
Pretreatment before LPS (1 µg/mL); untreated and LPS-only controls.
Co-treatment
LPS inflammatory challenge.
Reported limits
Vehicle and purity unspecified; no gastrodin-only group.
Methods and source locations

Compound reported in the paper: Gastrodin; Compound label in the paper: gastrodin

Findings apply to the named research material and specified model; no analytical or performance validation of an Adooq lot.

Figure 7A–E and caption; Methods: Cells and treatments, Western blot analysis, Statistical analysis; Discussion final paragraphs

Phosphorylated IκB-α, CREB, ERK1/2, JNK and p38 MAPK: Phospho-IκB-α and phospho-CREB normalized to β-actin; phospho-MAPKs normalized to corresponding total MAPK. — Figure 7A–E and caption; Results: Gastrodin decreases LPS-induced phosphorylation of MAPKs family

Gastrodin co-treatment in zinc-challenged C6 cells

Cell-based study · Rat C6 astroglial cell line [3]

Co-treatment improved the MTT signal at 50 and 100 µM gastrodin. At 250 µM, Figure 3A lacks a significance marker; benefit was not monotonic across the tested range.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
MTT viability relative to untreated cellsCell viability (%) Zinc alone: 50.9 ± 2.8%; zinc + 100 µM gastrodin: 74.9 ± 3.7% (n=4; mean ± SEM). Figure 3A marks 50 and 100 µM p<0.01 versus zinc alone; 250 µM is unmarked.[3]

Literature-Reported Treatment Conditions

Treatment concentration
50, 100 or 250 µM
Exposure duration
24 h co-treatment
Method
Co-treatment with 50 µM zinc sulfate; untreated and zinc-only controls.
Co-treatment
Zinc sulfate is the injury challenge.
Reported limits
The cell-assay gastrodin vehicle is not specified separately; the DMSO statement occurs in the animal Drug injection subsection.
Methods and source locations

Compound reported in the paper: Gastrodin; Compound label in the paper: GAS

Findings apply to the named research material and specified model; no analytical or performance validation of an Adooq lot.

Figure 3A and caption; Methods: C6 astroglial cell culture and Zn2+ treatment, Cell viability assays, Statistical analysis; Results: Suppression of Zn2+-induced C6 astroglial death by GAS

MTT viability relative to untreated cells: MTT assay; absorbance at 550 nm. n=4 is retained as reported; biological independence is not specified. — Figure 3A and corresponding Results paragraph

Senescence markers and HO-1 inhibitor sensitivity in HUVECs

Cell-based study · Human umbilical vein endothelial cells (HUVECs; ATCC), hydrogen peroxide senescence model [2]

Gastrodin lowered senescence markers and increased nuclear Nrf2 and HO-1. SnPPIX attenuated the marker reductions, supporting HO-1 involvement without establishing direct target engagement or genetic necessity.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
p16/p21 protein, SA β-gal-positive cells, nuclear Nrf2 and HO-1 proteinRelative protein / positive-cell fraction 50 and 100 µM reduced senescence markers. With 100 µM gastrodin, SnPPIX increased p16, p21 and SA β-gal positivity relative to gastrodin plus H2O2. No exact plotted means inferred.[2]
Gastrodin-only viability controlCCK-8 signal No cytotoxicity reported after 24 h at 6.25–200 µM.[2]

Literature-Reported Treatment Conditions

Treatment concentration
50 or 100 µM; inhibitor comparison used 100 µM
Exposure duration
6 h gastrodin pretreatment; 24 h follow-up after oxidative challenge. Results §3.2 describes a 2 h H2O2 exposure.
Method
100 µM H2O2 model; SnPPIX 20 µM for 2 h before gastrodin in inhibitor experiments.
Co-treatment
Separate HO-1 inhibitor control: SnPPIX, not a combined therapeutic efficacy claim.
Reported limits
Vehicle unspecified. General §2.1 and §3.2 differ in wording around the H2O2 exposure/follow-up; washout timing is not resolved. No SnPPIX-only senescence arm in Figure 5.
Methods and source locations

Compound reported in the paper: Gastrodin; Compound label in the paper: GAS

Findings apply to the named research material and specified model; no analytical or performance validation of an Adooq lot.

Figures 2B, 3A–E, 5A–I; Methods §§2.1–2.3, 2.6–2.7; Results §§3.2–3.3, 3.5; Discussion

p16/p21 protein, SA β-gal-positive cells, nuclear Nrf2 and HO-1 protein: Immunoblot densitometry (GAPDH; nuclear Nrf2 normalized to Histone H3 in Figure 5C) and SA β-gal staining. Methods §2.7: mean ± SD from at least three independent experiments. — Figures 3A–E and 5A–I; Results §§3.3, 3.5

Gastrodin-only viability control: CCK-8 viability assay; this control does not establish long-term safety. — Figure 2B; Results §3.2; Methods §§2.1–2.2

Gastrodin (Gastrodine) In Vivo Studies

In male rats after MCAO, a single gastrodin injection was associated with smaller infarcts and lower neurological deficit scores at 24 h versus treatment-naïve MCAO controls. Benefits were greatest at 40 mg/kg among the tested doses, and delayed dosing was less consistent. A matched DMSO-only MCAO group was not described. [3]

Acute postischemic outcomes in rats

Animal study · Male Sprague–Dawley rats, 8–9 weeks; 60 min middle cerebral artery occlusion (MCAO) [3]

A single gastrodin injection after MCAO was associated with smaller infarcts and lower neurological deficit scores at 24 h versus treatment-naïve MCAO controls. The response was non-monotonic and less consistent with delayed dosing.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Infarct volume as percentage of treatment-naïve MCAO controlRelative infarct volume (%) 40 mg/kg at 1 h: 22.2 ± 5.6% (n=5, p<0.01); 80 mg/kg at 1 h: 56.8 ± 12.6% (n=5); 40 mg/kg at 6 h: 43.9 ± 9.6% (n=4, p<0.05). Mean ± SEM.[3]
Modified Neurological Severity Score (0–18; higher indicates greater deficit)mNSS Control: 13.7 ± 0.4 (n=8). At 1 h, 20/40/80 mg/kg: 8.3 ± 0.5 (n=7), 4.3 ± 0.9 (n=4), 8.3 ± 0.9 (n=4). At 6 h: 9.0 ± 2.3, 6.0 ± 0.7, 8.5 ± 2.1 (each n=4). Mean ± SEM.[3]

Conditions shared by the study groups

Route
Intraperitoneal
Frequency
Single injection
Vehicle
DMSO; vehicle concentration/volume not specified.
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Injection 1 h after MCAO
20, 40 or 80 mg/kg
Treatment-naïve MCAO rats; sham and gastrodin-only control images also shown in Figure 1.40 mg/kg produced the largest reported benefit. Figure 1 marks infarct reduction at 40 and 80 mg/kg, with no marker at 20 mg/kg. Figure 2 marks lower mNSS at all three doses.[3]
Injection 6 h after MCAO
20, 40 or 80 mg/kg
Treatment-naïve MCAO rats; sham and gastrodin-only control images also shown in Figure 1.Only 40 mg/kg carries significance markers for infarct volume and mNSS in Figures 1–2; 20 and 80 mg/kg are unmarked.[3]
Injection 1 h after MCAO
Model: Male Sprague–Dawley rats, 8–9 weeks; 60 min middle cerebral artery occlusion (MCAO)
Treatment course: 1 h post-MCAO; assessed 24 h post-MCAO
Reported limits: No matched DMSO-only MCAO group described; endpoint-specific n varies.
Injection 6 h after MCAO
Model: Male Sprague–Dawley rats, 8–9 weeks; 60 min middle cerebral artery occlusion (MCAO)
Treatment course: 6 h post-MCAO; assessed 24 h post-MCAO
Reported limits: No matched DMSO-only MCAO group described; endpoint-specific n varies.
Methods and source locations

Compound reported in the paper: Gastrodin; Compound label in the paper: GAS

Findings apply to the named research material and specified model; no analytical or performance validation of an Adooq lot.

Figures 1–2 and captions; Table 1; Methods: Experimental animals, Drug injection, Infarct volume assessment, Behavioral testing, Statistical analysis

Infarct volume as percentage of treatment-naïve MCAO control: TTC staining at 1 day; edema-corrected infarct volumes. Percentages transcribed from Results, not estimated from the mm³ graph. — Results: Neuroprotective effects of GAS in the postischemic brain; Figure 1A–B

Modified Neurological Severity Score (0–18; higher indicates greater deficit): Motor, sensory, reflex and balance composite at 1 day. Figure 2 marks all 1 h groups p<0.01, but only 40 mg/kg at 6 h p<0.05 versus MCAO control. — Results: Improvements in neurological deficits after MCAO by GAS; Figure 2

Injection 1 h after MCAO · Figures 1–2; corresponding Results; Methods: Drug injection

Injection 6 h after MCAO · Figures 1–2; corresponding Results; Methods: Drug injection

Specifications

Manufacturer Adooq Bioscience
CAS Number 62499-27-8
Formula C13H18O7
Molecular Weight 286.3
Synonyms Gastrodine
SMILES
C1=CC(=CC=C1CO)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 43 mg/mL (150.2 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Gastrodin (Gastrodine) Research References

  1. [1] Dai JN, Zong Y, Zhong LM, et al. Gastrodin inhibits expression of inducible NO synthase, cyclooxygenase-2 and proinflammatory cytokines in cultured LPS-stimulated microglia via MAPK pathways. PloS one (2011). PMID: 21765922 DOI: 10.1371/journal.pone.0021891 Source material
  2. [2] Tong P, Tian K, Bi J, et al. Gastrodin alleviates premature senescence of vascular endothelial cells by enhancing the Nrf2/HO-1 signalling pathway. Journal of cellular and molecular medicine (2024). PMID: 38146239 DOI: 10.1111/jcmm.18089 Source material
  3. [3] Luo L, Kim SW, Lee HK, et al. Gastrodin exerts robust neuroprotection in the postischemic brain via its protective effect against Zn2+-toxicity and its anti-oxidative effects in astrocytes. Animal cells and systems (2018). PMID: 30533266 DOI: 10.1080/19768354.2018.1549099 Source material

Added to your cart

View Cart Checkout
Loading...